Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CGEN vs ACRS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: CGEN 5 – 1 ACRS Matrix Metrics: CGEN 9 – 1 ACRS

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas ACRS carries 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin).

  • Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGEN vs ACRS
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.38
-6.24% 1D
Market Cap $548.0M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.57β · 75% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 41.0 Fund 54.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $3.86 · SMA50: $4.33

6-Pillar Scorecard Institutional Category Breakdown (CGEN 5 – 1 ACRS)

Columns: Metric · CGEN · ACRS
1. Valuation Multiples CGEN
Forward P/E 12.4x N/M
Trailing P/E 5.2x N/M
PEG Ratio 1.29x N/M
EV / Revenue 2.5x 85.6x
2. Growth & Scale CGEN
Revenue Growth (YoY) +102.1% -55.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $76M $6.4M
Market Cap $193.2M $548.0M
3. Profitability & Quality CGEN
Gross Margin 86.2% N/A
Operating Margin 41.3% -1412.4%
Net Profit Margin 47.9% 0.0%
Return on Equity (ROE) 57.2% -55.5%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) $32M EBITDA -$75M
Cash Flow Margin 41.9% EBITDA Mgn N/A
Net Cash / Leverage $4.3M Net Cash $1.11 Book/Sh · -55.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACRS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 89.7% (57th %ile) 60.7% (1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity 44.9% of Rev ($34M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGEN (9) vs ACRS (1)
Institutional Metric CGEN ACRS Criterion Row Edge
Market Capitalization
Scale
$193.2M $548.0M Larger Scale ACRS
Trailing P/E Ratio
Valuation
5.2x N/M Lower Multiple CGEN
Forward P/E Ratio
Valuation
12.4x N/M Lower Multiple CGEN
Revenue Growth (YoY)
Growth
+102.1% -55.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
41.3% -1412.4% Higher Margin CGEN
Net Profit Margin
Profitability
47.9% 0.0% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
57.2% -55.5% Higher ROE CGEN
52-Week Range Position
Momentum
33% ($1–$3) 26% ($2–$7) Stronger Trend CGEN
Beta / 30D Volatility
Risk Regime
1.44β · 62% Vol 1.57β · 75% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite CGEN
Trailing 12M Revenue (USD)
Operating Scale
$76M $6.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.29x PEG · 2.5x EV/Rev N/M PEG · 85.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$32M EBITDA ($4.3M Net Cash) -$75M ($1.11 Book/Sh · -55.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +5.41 pp
CGEN: +2.54% · ACRS: -2.87%
3M Horizon CGEN +30.31 pp
CGEN: -17.21% · ACRS: -47.52%
6M Horizon ACRS +1.97 pp
CGEN: -26.01% · ACRS: -24.04%
1Y Horizon ACRS +10.96 pp
CGEN: +23.17% · ACRS: +34.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGEN Revenue ACRS Revenue CGEN Op. Margin ACRS Op. Margin Margin Leader
FY2018 $20M $10M -130.5% -1378.3% CGEN
FY2019 N/A $0M N/A -2627.3% ACRS
FY2020 $0M $10M -1574.8% -785.4% ACRS
FY2021 $10M $10M -584.6% -1327.1% CGEN
FY2022 $10M $30M -471.7% -302.0% ACRS
FY2023 $30M $30M -38.8% -311.6% CGEN
FY2024 $30M $20M -53.4% -758.2% CGEN
FY2025 $70M $10M 43.1% -975.9% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
130d in phase · OBV NEUTRAL
Current IV 60.7%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $548.0M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CGEN vs ACRS Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CGEN carries a Unified Composite Score of 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin), whereas ACRS carries 44.7/100 (HOLD) at $3.38 (N/M Forward P/E, -1412.4% operating margin). Technical & Structure Timing Caution: CGEN is currently in a Breakdown options structure phase (RSI 46.9); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: CGEN posts +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin), compared with ACRS at -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CGEN cumulative revenue shifted +250.0% while ACRS shifted +0.0%. In operating R&D and SG&A reinvestment, CGEN deploys 44.9% of Rev ($34M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACRS.

CGEN screens cheaper on headline valuation multiples. CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin), whereas ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 85.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGEN (57.2% ROE) versus ACRS (-55.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk). By comparison, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.